vs
Side-by-side financial comparison of Humacyte, Inc. (HUMA) and Lakeshore Acquisition III Corp. (LCCC). Click either name above to swap in a different company.
Lakeshore Acquisition III Corp. is the larger business by last-quarter revenue ($717.3K vs $467.0K, roughly 1.5× Humacyte, Inc.).
Humacyte, Inc. is a clinical-stage biotechnology firm focused on developing and commercializing universally implantable off-the-shelf bioengineered human tissues and therapeutic products. Its core offerings target unmet needs in vascular care, trauma treatment and regenerative medicine, serving patients and healthcare partners worldwide.
HUMA vs LCCC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $467.0K | $717.3K |
| Net Profit | — | $486.8K |
| Gross Margin | -1844.8% | — |
| Operating Margin | -6603.0% | -32.1% |
| Net Margin | — | 67.9% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.19 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $467.0K | — | ||
| Q3 25 | $753.0K | $717.3K | ||
| Q2 25 | $301.0K | $467.3K | ||
| Q1 25 | $517.0K | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q4 25 | — | — | ||
| Q3 25 | $-17.5M | $486.8K | ||
| Q2 25 | $-37.7M | $216.5K | ||
| Q1 25 | $39.1M | — | ||
| Q3 24 | $-39.2M | — | ||
| Q2 24 | $-56.7M | — | ||
| Q1 24 | $-31.9M | — |
| Q4 25 | -1844.8% | — | ||
| Q3 25 | 65.5% | — | ||
| Q2 25 | 29.2% | — | ||
| Q1 25 | 71.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -6603.0% | — | ||
| Q3 25 | -3239.0% | -32.1% | ||
| Q2 25 | -9876.1% | -53.7% | ||
| Q1 25 | -4484.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -2325.4% | 67.9% | ||
| Q2 25 | -12511.0% | 46.3% | ||
| Q1 25 | 7570.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $-0.11 | $0.08 | ||
| Q2 25 | $-0.24 | $0.06 | ||
| Q1 25 | $0.28 | — | ||
| Q3 24 | $-0.33 | — | ||
| Q2 24 | $-0.48 | — | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.5M | — |
| Total DebtLower is stronger | $35.4M | — |
| Stockholders' EquityBook value | $3.1M | $-1.6M |
| Total Assets | $116.4M | $71.0M |
| Debt / EquityLower = less leverage | 11.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.5M | — | ||
| Q3 25 | $19.5M | — | ||
| Q2 25 | $38.0M | — | ||
| Q1 25 | $62.8M | — | ||
| Q3 24 | $20.6M | — | ||
| Q2 24 | $93.6M | — | ||
| Q1 24 | $115.5M | — |
| Q4 25 | $35.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.1M | — | ||
| Q3 25 | $-4.8M | $-1.6M | ||
| Q2 25 | $4.1M | $-1.4M | ||
| Q1 25 | $36.0M | — | ||
| Q3 24 | $-63.7M | — | ||
| Q2 24 | $-28.3M | — | ||
| Q1 24 | $26.2M | — |
| Q4 25 | $116.4M | — | ||
| Q3 25 | $91.5M | $71.0M | ||
| Q2 25 | $138.8M | $70.5M | ||
| Q1 25 | $162.6M | — | ||
| Q3 24 | $114.8M | — | ||
| Q2 24 | $138.3M | — | ||
| Q1 24 | $161.5M | — |
| Q4 25 | 11.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.1M | $-206.3K |
| Free Cash FlowOCF − Capex | $-26.2M | — |
| FCF MarginFCF / Revenue | -5602.4% | — |
| Capex IntensityCapex / Revenue | 8.4% | — |
| Cash ConversionOCF / Net Profit | — | -0.42× |
| TTM Free Cash FlowTrailing 4 quarters | $-105.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.1M | — | ||
| Q3 25 | $-23.9M | $-206.3K | ||
| Q2 25 | $-26.4M | $-218.3K | ||
| Q1 25 | $-28.6M | — | ||
| Q3 24 | $-22.9M | — | ||
| Q2 24 | $-21.3M | — | ||
| Q1 24 | $-27.3M | — |
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $-24.0M | — | ||
| Q2 25 | $-27.0M | — | ||
| Q1 25 | $-28.8M | — | ||
| Q3 24 | $-23.8M | — | ||
| Q2 24 | $-21.5M | — | ||
| Q1 24 | $-27.7M | — |
| Q4 25 | -5602.4% | — | ||
| Q3 25 | -3181.0% | — | ||
| Q2 25 | -8963.8% | — | ||
| Q1 25 | -5576.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 8.4% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | 188.7% | — | ||
| Q1 25 | 44.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.42× | ||
| Q2 25 | — | -1.01× | ||
| Q1 25 | -0.73× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
